Fig. 3: Anti-miR-873-5p attenuates BDL-induced liver injury through GNMT regulation.
From: MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
(a) Time scheme of the BDL mouse model with anti-miR-873-5p (time points indicated). MiR-873-5p expression (b) and GNMT mRNA and protein expression (c) in the liver of miR-Ctrl-BDL and anti-miR-873-5p-BDL mice. (d) Serum transaminases (ALT and AST) levels in miR-Ctrl and anti-miR-873-5p-treated-mice at 7 days of BDL. (e) Caspase 3 activity and WB analysis of apoptosis mediated by PARP cleavage. (f) H&E, F4/80, Sirius Red, αSMA, and CK19 staining in liver sections from miR-Ctrl and miR-873-5p-inhibited-mice at 7 days of BDL. (g) qPCR analysis of indicated genes in total liver extracts at 7 days of BDL. (h) WB analysis with indicated Ab in total liver of WT, BDL-Ctrl and anti-miR-873-BDL mice at 7 days. Densitometry analyses of WB are shown in Supp. Fig. 2B. Data normalized as fold change vs. control. Error bars represent the means ± SEM (N = 4). Statistical significance was determined by the Student’s t-test or ANOVA when more than two groups were compared. p < 0.05*; p < 0.01**; p < 0.001***
